Tamarly Intelligence
Deal · Agreement signed

Fulcrum Therapeutics, Inc. and Slate surviving the merger as the surviving

First filed 17 Aug 2026, 1 filing.

The deal
Buyer
Fulcrum Therapeutics, Inc.
Target
Slate surviving the merger as the surviving
Status
Agreement signed
Region
US
Entry into a Material Definitive Agreement.

Source: The filing (SEC Form 8-K)

With a free account

A free account opens 10 full pages a month and lets you follow this page: alerts on the next filing, buyer lists, exports.

Start freeSign in

Research from public records, not investment advice. Tamarly holds no investment positions. By reading these pages you accept the Terms of Use; figures can be late or wrong, so check the linked source before relying on one. Terms and policies.

Fulcrum Therapeutics, Inc. and Slate surviving the merger as the surviving: deal agreed (2026) | Tamarly